MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Biotechnology_Natural Killer Cell Therapies
Nkarta, Inc. (NASDAQ: NKTX)*
Organization & Developments: Nkarta
Parents
Nkarta, Inc. (NASDAQ: NKTX)*
Children
*Experimental CAR-T therapy
2022: Nkarta: A Buy On Pullback With Valuation At Lows_ seekingalpha.com
2022: Nkarta: Under The Radar Company With Brilliant Results_ seekingalpha.com
2023: Nkarta: Trying To Be The NK Story That Actually Succeeds_ seekingalpha.com
2024: Nkarta (NKTX) Stock: Looking For Upside
2024: Nkarta continues pivot to autoimmune by shelving lymphoma program for CAR NK candidate
2024: Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
2024: Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
2024: Nkarta: NK Cell Therapy Advancement On Two Fronts
2024: Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
2024: Nkarta: Possible Upside From H1 Update, If Positive
2024: Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race
2024: Nkarta's SWOT analysis: cell therapy innovator's stock faces pivotal phase
2024: Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey
2024: Nkarta’s NKX019 Shows Potential in Lymphoma Treatment_www.tipranks.com
2025: Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program
2025: Nkarta, Inc.: Trying To Find Space In A Crowded Place_ seekingalpha.com
Jumps
Finance & Acquisitions: Nkarta
Key People: Nkarta